Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 20/20 | 0.64 |
| ▸ | GIPR | P48546 | 4/20 | 0.64 |
| ▸ | GLP1R | P43220 | 2/20 | 0.64 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.64 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.64 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.64 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.64 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.64 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.64 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.64 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.64 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086897 | 1.00 | GCGR (0.64) | GCGRGIPRGLP1RADCY6ADCY3 | |
| SCHEMBL4091710 | 1.00 | GCGR (0.64) | GCGRGIPRGLP1RADCY6ADCY3 | |
| SCHEMBL6190620 | 0.90 | GCGR (0.60) | GCGRGIPRGLP1RADCY6ADCY3 | |
| SCHEMBL2663532 | 0.90 | GCGR (0.60) | GCGRGIPRGLP1RADCY6ADCY3 | |
| SCHEMBL6189703 | 0.90 | GCGR (0.60) | GCGRGIPRGLP1RADCY6ADCY3 | |
| SCHEMBL4258393 | 0.90 | GCGR (0.79) | GCGRGIPRGLP1RADCY6ADCY3 | |
| SCHEMBL4082039 | 0.88 | GCGR (0.81) | GCGRGIPRGLP1RADCY6ADCY3 | |
| SCHEMBL2663416 | 0.88 | GCGR (0.81) | GCGRGIPRGLP1RADCY6ADCY3 | |
| SCHEMBL2663130 | 0.86 | GCGR (0.84) | GCGRGIPRGLP1RADCY6ADCY3 | |
| SCHEMBL4085478 | 0.85 | GCGR (0.75) | GCGRGIPRGLP1RADCY6ADCY3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.